211 related articles for article (PubMed ID: 32605217)
1. Promoter Methylation of Selected Genes in Non-Small-Cell Lung Cancer Patients and Cell Lines.
Sarne V; Huter S; Braunmueller S; Rakob L; Jacobi N; Kitzwögerer M; Wiesner C; Obrist P; Seeboeck R
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605217
[TBL] [Abstract][Full Text] [Related]
2. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.
Kontic M; Stojsic J; Jovanovic D; Bunjevacki V; Ognjanovic S; Kuriger J; Puumala S; Nelson HH
Clin Lung Cancer; 2012 Jul; 13(4):297-303. PubMed ID: 22169480
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients.
Pastuszak-Lewandoska D; Kordiak J; Migdalska-Sęk M; Czarnecka KH; Antczak A; Górski P; Nawrot E; Kiszałkiewicz JM; Domańska D; Brzeziańska-Lasota E
Respir Res; 2015 Jun; 16(1):76. PubMed ID: 26112163
[TBL] [Abstract][Full Text] [Related]
4. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC).
Ji M; Guan H; Gao C; Shi B; Hou P
BMC Cancer; 2011 Apr; 11():147. PubMed ID: 21507233
[TBL] [Abstract][Full Text] [Related]
5. WT1 promotes invasion of NSCLC via suppression of CDH1.
Wu C; Zhu W; Qian J; He S; Wu C; Chen Y; Shu Y
J Thorac Oncol; 2013 Sep; 8(9):1163-9. PubMed ID: 23945386
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
7. Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer.
Zhai X; Li SJ
Asian Pac J Cancer Prev; 2014; 15(12):4925-8. PubMed ID: 24998565
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of expression level and methylation profile of
Mohammadi Z; Azad M; Foroughi F; Khojastehpour S; Gheibi N; Samiee-Rad F; Maali A; Ahmadi MH
J Cancer Res Ther; 2021; 17(6):1328-1334. PubMed ID: 34916361
[TBL] [Abstract][Full Text] [Related]
9. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer.
Tang X; Yin X; Xiang T; Li H; Li F; Chen L; Ren G
Cancer Biomark; 2012-2013; 12(1):11-9. PubMed ID: 23321465
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.
Miao Y; Wang L; Zhang X; Xu X; Jiang G; Fan C; Liu Y; Lin X; Yu J; Zhang Y; Wang E
PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757
[TBL] [Abstract][Full Text] [Related]
11. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J
Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445
[TBL] [Abstract][Full Text] [Related]
12. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
[TBL] [Abstract][Full Text] [Related]
13. [Meta-analysis of the Association between RASSF1A Gene Promoter Methylation and Non-small Cell Lung Cancer].
Wei H; Fang N; Guo L; Wu Z; Zhou Q
Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):443-50. PubMed ID: 26182870
[TBL] [Abstract][Full Text] [Related]
14. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
15. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
[TBL] [Abstract][Full Text] [Related]
16. The expression of ADAM23 and its correlation with promoter methylation in non-small-cell lung carcinoma.
Hu C; Lv H; Pan G; Cao H; Deng Z; Hu C; Wen J; Zhou J
Int J Exp Pathol; 2011 Oct; 92(5):333-9. PubMed ID: 21429053
[TBL] [Abstract][Full Text] [Related]
17. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
[TBL] [Abstract][Full Text] [Related]
18. Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer.
Walter RFH; Rozynek P; Casjens S; Werner R; Mairinger FD; Speel EJM; Zur Hausen A; Meier S; Wohlschlaeger J; Theegarten D; Behrens T; Schmid KW; Brüning T; Johnen G
PLoS One; 2018; 13(5):e0195716. PubMed ID: 29851970
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
[TBL] [Abstract][Full Text] [Related]
20. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers.
Imoto I; Izumi H; Yokoi S; Hosoda H; Shibata T; Hosoda F; Ohki M; Hirohashi S; Inazawa J
Cancer Res; 2006 May; 66(9):4617-26. PubMed ID: 16651412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
